Read more
Advanced renal cell carcinoma is refractory to nearly forms of systemic therapy. For this reason the last decade has seen numerous research groups working on immunotherapeutic strategies against it. Immunotherapy of Renal Cell Carcinoma reports the contributions of most of the world's leading research groups to two international conferences on the immunobiology of this illness. Sixteen chapters divided in experimental and clinical studies provide an overview of immunotherapy in renal cell carcinoma and a discussion of new laboratory approaches to this topic.
Immunotherapy is after surgery, chemotherapy and radiotherapy the fourth treatment modality in the armamentarium of the renal cell carcinoma. This book provides an overview of the whole field of immunotherapy and gives a state of the art of experimental and clinical achievements.
List of contents
Experimental Data.- Considerations in Immunotherapy of Genitourinary Neoplasia.- Murine Renal Cancer (Renca) Model: Background and Preclinical Studies.- Renal Cell Carcinoma: Experimental Metastases.- Oncogenes in Renal Cell Carcinoma.- Molecular Basis and Clinical Relevance of MDR1 Gene Expression in Renal Cell Carcinoma.- Radioimmunoconjugates in Renal Cell Carcinoma.- Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems.- Clinical Experience with Biological Response Modifiers in Renal Cell Carcinoma.- Rationale for Immunotherapy in Renal Cell Carcinoma.- Treatment of Renal Cell Carcinoma with Interferon.- Combination Therapy with Interferon in Renal Cell Carcinoma.- Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer: Updated Results.- Monotherapy and Combination Therapy with Interferon-?, Interferon-?, and Tumor Necrosis Factor-? in Metastatic Renal Cell Carcinoma.- Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2.- Direct Lymphatic Immunotherapy for Metastatic Renal Cell Carcinoma.- Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience.- Tumor Infiltrating Lymphocytes in Human Renal Cell Carcinoma: Adoptive Immunotherapy and Characterization of Interleukin-2 Expanded Tumor-Infiltrating Lymphocytes.- Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization.
Summary
Immunotherapy is after surgery, chemotherapy and radiotherapy the fourth treatment modality in the armamentarium of the renal cell carcinoma. This book provides an overview of the whole field of immunotherapy and gives a state of the art of experimental and clinical achievements.
